PKCδ Protects against Lupus Autoimmunity.

Area of Science:

• Immunology
• Molecular Biology
• Autoimmunity

Background:

• Systemic lupus erythematosus (SLE) is an autoimmune disease driven by autoantibodies, particularly anti-dsDNA IgGs.
• Protein kinase C delta (PKCδ) is a critical regulator of immune tolerance, but its precise role in preventing lupus is not fully understood.
• Reduced sphingomyelin synthase 2 (SMS2) expression in B cells is observed in lupus patients, potentially impairing PKCδ function.

Purpose of the Study:

• To review and provide mechanistic insights into the B cell tolerance activity of PKCδ.
• To discuss the therapeutic potential of targeting the SMS2/PKCδ pathway in the germinal center (GC) for SLE treatment.

Main Methods:

• Review of relevant scientific literature on PKCδ, SMS2, and B cell tolerance in SLE.
• Analysis of the role of PKCδ in selective deletion of autoreactive B cells within the GC.
• Examination of the impact of SMS2 expression levels on PKCδ activity and lupus pathogenesis.

Main Results:

• PKCδ selectively deletes B cells producing anti-dsDNA antibodies in the GC, a key tolerance mechanism.
• The tolerance function of PKCδ is activated by SMS2, an enzyme often downregulated in lupus B cells.
• Pharmacological enhancement of the SMS2/PKCδ pathway reduced lupus severity in mouse models.

Conclusions:

• PKCδ plays a vital role in preventing lupus autoimmunity by maintaining B cell tolerance.
• Targeting the SMS2/PKCδ pathway in the GC represents a promising therapeutic strategy for selective inhibition of lupus autoimmunity.